(Q36477461)

14 August 2017

1 reference

title

Blunting the Swiss army knife of hepatitis C virus: inhibitors of NS3/4A protease (English)

1 reference

14 August 2017

1 reference

Peter W White

1

1 reference

PubMed ID

16697895

14 August 2017

Montse Llinas-Brunet

series ordinal

2

1 reference

PubMed ID

16697895

14 August 2017

Michael Bös

series ordinal

3

1 reference

14 August 2017

1 January 2006

1 reference

Progress in medicinal chemistry

14 August 2017

1 reference

14 August 2017

44

1 reference

14 August 2017

65-107

1 reference

Detection of genome-scale ordered RNA structure (GORS) in genomes of positive-stranded RNA viruses: Implications for virus evolution and host persistence

14 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Hepatitis C in state correctional facilities

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Hepatitis C virus infection in post-transfusion hepatitis. An analysis with first- and second-generation assays

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Cytokines and chemokines in the immune response to hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Inhibitors of hepatitis C virus NS3.4A protease: an overdue line of therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Genetic diversity and evolution of hepatitis C virus--15 years on

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Evidence for a new hepatitis C virus antigen encoded in an overlapping reading frame

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

A nucleotide binding motif in hepatitis C virus (HCV) NS4B mediates HCV RNA replication

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

The origin of hepatitis C virus genotypes.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Hepatitis C virus genetic variability: pathogenic and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Interferons, interferon-like cytokines, and their receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Diagnosis, management, and treatment of hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Modelling how ribavirin improves interferon response rates in hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Tinkering and tailoring with HCV therapy: can we get away with less?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Past, present, and future hepatitis C treatments

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

A zinc binding site in viral serine proteinases

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: A 2.2 Å resolution structure in a hexagonal crystal form

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Structure and function of the hepatitis C virus NS3-NS4A serine proteinase.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

The NS3/4A proteinase of the hepatitis C virus: unravelling structure and function of an unusual enzyme and a prime target for antiviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Peptide-based inhibitors of the hepatitis C virus serine protease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Role of charged residues in the catalytic mechanism of hepatitis C virus NS3 protease: electrostatic precollision guidance and transition-state stabilization

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Probing the active site of the hepatitis C virus serine protease by fluorescence resonance energy transfer

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Interferon regulatory factors: the next generation

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Regulation of Interferon Regulatory Factor-3 by the Hepatitis C Virus Serine Protease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Complex formation between the hepatitis C virus serine protease and a synthetic NS4A cofactor peptide

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Multiple determinants influence complex formation of the hepatitis C virus NS3 protease domain with its NS4A cofactor peptide.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Construction, expression, and characterization of a novel fully activated recombinant single-chain hepatitis C virus protease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Rational design and functional expression of a constitutively active single-chain NS4A-NS3 proteinase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Development of a high throughput scintillation proximity assay for hepatitis C virus NS3 protease that reduces the proportion of competitive inhibitors identified

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

A continuous assay of hepatitis C virus protease based on resonance energy transfer depsipeptide substrates

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

A continuous spectrophotometric assay for the hepatitis C virus serine protease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

A scintillation proximity active site binding assay for the hepatitis C virus serine protease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Replication of the hepatitis C virus in cell culture

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

A novel method for analysis of viral proteinase activity encoded by hepatitis C virus in cultured cells

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

In vivo assay for hepatitis C viral serine protease activity using a secreted protein

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Replication Studies Using Genotype 1a Subgenomic Hepatitis C Virus Replicons

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Adaptive mutations producing efficient replication of genotype 1a hepatitis C virus RNA in normal Huh7 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Efficient initiation of HCV RNA replication in cell culture

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

The hepatitis C virus (HCV)-Trimera mouse: a model for evaluation of agents against HCV.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Hepatitis C virus replication in mice with chimeric human livers

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Pyrrolidine-5,5-trans-lactams. 5. Pharmacokinetic optimization of inhibitors of hepatitis C virus NS3/4A protease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Does the hepatitis C virus replicate in cells of the hematopoietic lineage?

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Detection and Analysis of Hepatitis C Virus Sequences in Cerebrospinal Fluid

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Evidence of viral replication in circulating dendritic cells during hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Identification of unique hepatitis C virus quasispecies in the central nervous system and comparative analysis of internal translational efficiency of brain, liver, and serum variants.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

An NS3 serine protease inhibitor abrogates replication of subgenomic hepatitis C virus RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Kinetic profile of a heterocyclic HCV replicon RNA synthesis inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Product inhibition of the hepatitis C virus NS3 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Peptide-based inhibitors of the hepatitis C virus NS3 protease: structure-activity relationship at the C-terminal position.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

A designed P1 cysteine mimetic for covalent and non-covalent inhibitors of HCV NS3 protease.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

NMR structural characterization of peptide inhibitors bound to the Hepatitis C virus NS3 protease: design of a new P2 substituent

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Solid-phase synthesis of peptidomimetic inhibitors for the hepatitis C virus NS3 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

A systematic approach to the optimization of substrate-based inhibitors of the hepatitis C virus NS3 protease: discovery of potent and specific tripeptide inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Potent inhibitors of the hepatitis C virus NS3 protease: design and synthesis of macrocyclic substrate-based beta-strand mimics

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Synthesis of BILN 2061, an HCV NS3 protease inhibitor with proven antiviral effect in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Phenethyl amides as novel noncovalent inhibitors of hepatitis C virus NS3/4A protease: discovery, initial SAR, and molecular modeling

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

SAR and pharmacokinetic studies on phenethylamide inhibitors of the hepatitis C virus NS3/NS4A serine protease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Novel, potent phenethylamide inhibitors of the hepatitis C virus (HCV) NS3 protease: probing the role of P2 aryloxyprolines with hybrid structures

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Novel azapeptide inhibitors of hepatitis C virus serine protease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Acyl sulfonamides as potent protease inhibitors of the hepatitis C virus full-Length NS3 (protease-helicase/NTPase): a comparative study of different C-terminals

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Structure-activity relationships for the selectivity of hepatitis C virus NS3 protease inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Prime site binding inhibitors of a serine protease: NS3/4A of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Inhibitors of hepatitis C virus NS3·4A protease 1. Non-Charged tetrapeptide variants

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Inhibitors of hepatitis C virus NS3.4A protease. Part 3: P2 proline variants

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Discovery of a novel bicycloproline P2 bearing peptidyl alpha-ketoamide LY514962 as HCV protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

P1 and P3 optimization of novel bicycloproline P2 bearing tetrapeptidyl alpha-ketoamide based HCV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Novel P4 truncated tripeptidyl alpha-ketoamides as HCV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

P4 and P1' optimization of bicycloproline P2 bearing tetrapeptidyl alpha-ketoamides as HCV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Glycine alpha-ketoamides as HCV NS3 protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Pyrrolidine-5,5-trans-lactams. 1. Synthesis and incorporation into inhibitors of hepatitis C virus NS3/4A protease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

The design of potent, non-peptidic inhibitors of hepatitis C protease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Pyrrolidine-5,5-trans-lactams. 2. The use of X-ray crystal structure data in the optimization of P3 and P4 substituents

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Design and synthesis of ethyl pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A protease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

P1 Phenethyl peptide boronic acid inhibitors of HCV NS3 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Design and synthesis of bicyclic pyrimidinone-based HCV NS3 protease inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Design and synthesis of potent, non-peptide inhibitors of HCV NS3 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Two antiviral compounds from the plant Stylogne cauliflora as inhibitors of HCV NS3 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Antiviral compounds from traditional Chinese medicines Galla Chinese as inhibitors of HCV NS3 protease

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Non-peptidic small-molecule inhibitors of the single-chain hepatitis C virus NS3 protease/NS4A cofactor complex discovered by structure-based NMR screening

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution

1 reference

https://api.crossref.org/works/10.1016%2FS0079-6468%2805%2944402-1

7 January 2021

10.1016/S0079-6468(05)44402-1

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16697895